Summary
Traditional radiation therapy for high risk and/or node positive prostate cancer typically involves 4-8 weeks of daily treatment with androgen deprivation therapy. Recent studies have shown that using fewer but larger doses of radiation, i.e. 5-treatment stereotactic ablative radiotherapy (SABR), is just as effective and safe, and this has now become one of the standard radiotherapy schedules for intermediate risk prostate cancer.
The question then is whether we can further reduce the number of treatments for prostate SABR while maintaining the cancer control rate and minimising side effects for high risk and/or node positive prostate cancer. This is an appealing option from a patient convenience and healthcare cost-saving point of view.
In this Australian Phase II trial of 5-treatment prostate and pelvic SABR, we aim to evaluate the efficacy, toxicity and quality of life outcomes of this treatment.
Participants will receive SABR to the prostate and pelvic lymph nodes, delivered in five fractions, one fraction per week.
The study will recruit two cohorts of participants:
- Cohort A: high-risk node negative prostate cancer
- Cohort B: node-positive non-metastatic prostate cancer.